Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications - Trial NCT06299761
Access comprehensive clinical trial information for NCT06299761 through Pure Global AI's free database. This Phase 1 trial is sponsored by Boundless Bio and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 42 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Boundless Bio
Timeline & Enrollment
Phase 1
Mar 28, 2024
Feb 01, 2027
Primary Outcome
Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-825,Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of BBI-825
Summary
BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase
 (RNR). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to
 determine the safety profile and identify the maximum tolerated dose and recommended Phase 2
 dose of BBI-825 administered as a single agent and in combination with select targeted
 therapies.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06299761
Non-Device Trial